ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Metabolism-Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53-Mutant Colon Cancer.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- ALNCR.TNM as a Novel Prognostic Tool for Cancer Survival.Journal of cachexia, sarcopenia and muscle · 2026Article
- The significance of the ketolytic gene OXCT1 in metabolism, intracellular signaling and disease development.Cellular and molecular life sciences : CMLS · 2026Review
- The Role of the Ketogenic Diet in Lung Cancer: Current Evidence and Future Perspectives.Cancers · 2026Review
- Low expression of OXCT1 promote colorectal cancer liver metastasis by upregulating CDK8 and β-catenin via H3 acetylation.Genes & diseases · 2026Article
- β-Hydroxybutyrate, a primary metabolite of ketogenic diets and its dual role in modulating colorectal cancer: from molecular mechanisms to therapeutic insights.Clinical and experimental medicine · 2026Review
- Lactylation in colorectal cancer: Unveiling novel mechanisms in metabolism, progression and therapeutic targeting.Clinical and translational medicine · 2026Review
- The Function and Mechanism of OXCT1 in Tumor Progression as a Critical Ketone Body Metabolic Enzyme.Biomolecules · 2025Review
- Marine natural product Methyl mycophenolate inhibits gastric cancer growth through regulating p53 and the downstream pathways.Cancer cell international · 2025Article
- Bulk and single-cell RNA sequencing analyses coupled with multiple machine learning to develop a glycosyltransferase associated signature in colorectal cancer.Translational oncology · 2024Article
- The ratio of PKM1/PKM2 is the key factor affecting the glucose metabolism and biological function of colorectal cancer cells.Translational cancer research · 2024Article
- Application of lncRNA-miRNA-mRNA ceRNA network analysis in the treatment of androgenic alopecia.Journal of clinical laboratory analysis · 2023Article
- Metabolism-Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53-Mutant Colon Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Comparative Expression Analysis ofCancer diagnosis & prognosisArticle
Corrections and comments
- Erratum issued
Authors and funding
24 authors at 5 institutions in 3 countries.
Meng TangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Hui XuDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Hongyan HuangDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Hao KuangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Chenxi WangLaboratory of Cell Engineering, Institute of Biotechnology, Research Unit of Cell Death Mechanism, 2021RU008, Chinese Academy of Medical Science, 20 Dongda Street, Beijing, 100071, China.
Qinqin LiDepartment of Gastrointestinal Surgery/ Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Xin ZhangDepartment of Pediatric Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.
Yizhong GeDepartment of Gastrointestinal Surgery/ Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Mengmeng SongDepartment of Gastrointestinal Surgery/ Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Xi ZhangDepartment of Gastrointestinal Surgery/ Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Ziwen WangDepartment of Gastrointestinal Surgery/ Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Chaobing MaLaboratory of Cell Engineering, Institute of Biotechnology, Research Unit of Cell Death Mechanism, 2021RU008, Chinese Academy of Medical Science, 20 Dongda Street, Beijing, 100071, China.
Jinlin KangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Wanfang ZhangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
You WangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Bo ZhangDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Xiaowei ZhangDepartment of Gastrointestinal Surgery/ Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Yongbing ChenDepartment of Gastrointestinal Surgery/ Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.
Minghua CongComprehensive Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Gerry MelinoDepartment of Experimental Medicine, TOR, University of Rome"Tor Vergata", Rome, 50-00133, Italy.
Xiaobin WangDepartment of Population, Family, and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health; and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA.
Fuxiang ZhouDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Qiang SunLaboratory of Cell Engineering, Institute of Biotechnology, Research Unit of Cell Death Mechanism, 2021RU008, Chinese Academy of Medical Science, 20 Dongda Street, Beijing, 100071, China.
Hanping ShiDepartment of Gastrointestinal Surgery/ Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 10038, China.ORCID 0000-0003-4514-8693
Capital Medical University · CNWuhan University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNJohns Hopkins University · USUniversity of Rome Tor Vergata · IT
Funding
Beijing Municipal Administration of Hospitals Incubating Program PX2021033Key Science & Technology Project of Beijing Educational Committee and Beijing Municipal Natural Science Foundation KZ202110025029National Key Research and Development Program 2022YFC3600100Natural Science Foundation of China 31970685Natural Science Foundation of China 32100608Natural Science Foundation of China 81773238Natural Science Foundation of China 82002918Science and Technology Fund of Zhongnan Hospital, Wuhan University cxpy2017053Youth Fund of Beijing Shijitan Hospital, CMU 2019-q02
Abstract
Although targeting cancer metabolism is a promising therapeutic strategy, clinical success depends on accurate molecular and metabolic subtyping. Here, this study reports two metabolism-based molecular subtypes associated with the ketogenic treatment of colon cancer: glycolytic (glycolysis
Indexed as
Colonic NeoplasmsTumor Suppressor Protein p53GlucoseHumansKetone BodiesKetonesGlucoseKetone BodiesKetonesTumor Suppressor Protein p53colon cancerketogenic therapymetabolic subtypeOXCT1p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.